1
|
Lupo A, Alifano M, Wislez M, Boulle G, Velut Y, Biton J, Cremer I, Goldwasser F, Leroy K, Damotte D. [Biomarkers predictive of PD1/PD-L1 immunotherapy in non-small cell lung cancer]. Rev Pneumol Clin 2018; 74:339-350. [PMID: 30337201 DOI: 10.1016/j.pneumo.2018.09.010] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
Immune checkpoint inhibitors (ICI), targeting the PD1/PD-L1 axis has shown their efficacy in lung cancer but only in a restricted population of patients, thus it is mandatory to identify biomarkers predicting the clinical benefit. In this article we will describe and analyzed biomarkers already published, from protein, to RNA and at last DNA markers, discussing each markers feasibility and interest. In the future, combined analysis of several markers will probably be proposed, particularly with the increasing complexity of therapy schema with molecules association.
Collapse
Affiliation(s)
- A Lupo
- UMRS 1138, Institut national de la santé et de la recherche médicale (Inserm), centre de recherche des cordeliers équipe « Cancer, Immune Control and Escape », Paris, France; Université Paris Descartes, 75006 Paris, France; Université Pierre et Marie-Curie Paris, 75005 Paris, France; Service de pathologie, hôpital Cochin, Assistance publique des hôpitaux de Paris (AP-HP), 75014 Paris, France
| | - M Alifano
- Université Paris Descartes, 75006 Paris, France; Service de chirurgie thoracique, hôpital Cochin, Assistance publique des hôpitaux de Paris (AP-HP), 75014 Paris, France
| | - M Wislez
- UMRS 1138, Institut national de la santé et de la recherche médicale (Inserm), centre de recherche des cordeliers équipe « Cancer, Immune Control and Escape », Paris, France; Université Paris Descartes, 75006 Paris, France; Université Pierre et Marie-Curie Paris, 75005 Paris, France; Service de pathologie, hôpital Cochin, Assistance publique des hôpitaux de Paris (AP-HP), 75014 Paris, France; Service de pneumologie, hôpital Tenon, Assistance publique des hôpitaux de Paris (AP-HP), 75014 Paris, France
| | - G Boulle
- UMRS 1138, Institut national de la santé et de la recherche médicale (Inserm), centre de recherche des cordeliers équipe « Cancer, Immune Control and Escape », Paris, France; Université Paris Descartes, 75006 Paris, France; Université Pierre et Marie-Curie Paris, 75005 Paris, France
| | - Y Velut
- UMRS 1138, Institut national de la santé et de la recherche médicale (Inserm), centre de recherche des cordeliers équipe « Cancer, Immune Control and Escape », Paris, France; Université Paris Descartes, 75006 Paris, France; Université Pierre et Marie-Curie Paris, 75005 Paris, France
| | - J Biton
- Laboratoire immunologie et immunopathologie-Li2P, Inserm UMR 1125, physiopathologie, cibles et thérapies de la polyarthrite rhumatoïde, Sorbonne Paris cité université Paris 13, 93000 Bobigny, France
| | - I Cremer
- UMRS 1138, Institut national de la santé et de la recherche médicale (Inserm), centre de recherche des cordeliers équipe « Cancer, Immune Control and Escape », Paris, France; Université Paris Descartes, 75006 Paris, France; Université Pierre et Marie-Curie Paris, 75005 Paris, France
| | - F Goldwasser
- Université Paris Descartes, 75006 Paris, France; Service d'oncologie médicale, hôpital Cochin, Assistance publique des hôpitaux de Paris (AP-HP), 75014 Paris, France
| | - K Leroy
- Université Paris Descartes, 75006 Paris, France; Service de génétique et biologie moléculaires, hôpital Cochin, Assistance publique des hôpitaux de Paris (AP-HP), 75014 Paris, France
| | - D Damotte
- UMRS 1138, Institut national de la santé et de la recherche médicale (Inserm), centre de recherche des cordeliers équipe « Cancer, Immune Control and Escape », Paris, France; Université Paris Descartes, 75006 Paris, France; Université Pierre et Marie-Curie Paris, 75005 Paris, France; Service de pathologie, hôpital Cochin, Assistance publique des hôpitaux de Paris (AP-HP), 75014 Paris, France.
| |
Collapse
|
2
|
Biton J, Santinon F, Lemeiter D, Boissier MC, Bessis N. A7.03 Il-33 inhibits experimental arthritis through CD25 +and CD25 -regulatory T cells activation. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-209124.134] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
3
|
Athari SK, Biton J, Hervé R, Raffaillac A, Lemeiter D, Herbelin A, Semerano L, Girard JP, Caux F, Boissier MC, Bessis N. A8.30 Collagen-induced arthritis and imiquimod-induced psoriasis development is unaffected by the absence of interleukin-33. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-207259.215] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
4
|
Thiolat A, Biton J, Decker P, Semerano L, Boissier MC, Pers YM, Jorgensen C, Plence PL, Bessis N. Reply: To PMID 24504799. Arthritis Rheumatol 2014; 66:2640-1. [PMID: 24891310 DOI: 10.1002/art.38717] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- A Thiolat
- INSERM U1125 and Sorbonne Paris Cité Université Paris 13
| | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Thiolat A, Denys A, Petit M, Biton J, Lemeiter D, Herve R, Lutomski D, Boissier MC, Bessis N. Interleukin-35 gene therapy exacerbates experimental rheumatoid arthritis in mice. Cytokine 2014; 69:87-93. [PMID: 25022966 DOI: 10.1016/j.cyto.2014.05.015] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2014] [Revised: 05/07/2014] [Accepted: 05/12/2014] [Indexed: 10/25/2022]
Abstract
Interleukin (IL)-35 was initially described as an immunosuppressive cytokine specifically produced by CD4(+)FoxP3(+) regulatory T cells (Treg). Since Treg play a major role in autoimmunity control and protect from inflammation, we aimed at evaluating the role of IL-35 in collagen-induced arthritis (CIA), a mouse model of rheumatoid arthritis (RA), using a non-viral gene transfer strategy. The clinical and histological effect of IL-35 was assessed in mice with CIA receiving an injection of two distinct plasmids encoding IL-35 gene (pIGneo-mIL-35 or pORF-mIL-35) 3 and 18 days after CIA induction. Treg and Th17 were characterized by flow cytometry in the spleen and lymph nodes of treated mice. Our results showed that whatever the plasmid used, IL-35 gene transfer resulted in a statistically significant increase in clinical scores of CIA compared to results with empty plasmid. The underlying cellular mechanisms of this effect were shown to be related to an increased Th17/Treg ratio in the spleen of pORF-mIL-35 treated mice. In conclusion, we show an unexpected but clear exacerbating effect of IL-35 gene transfer in an autoimmune and inflammatory RA model, associated with a modification of the Th17/Treg balance. Altogether, these result shows that this cytokine can promote chronic inflammation.
Collapse
Affiliation(s)
- A Thiolat
- INSERM, U1125, F-93017 Bobigny, France; Sorbonne Paris Cité Université Paris 13, F-93017 Bobigny, France
| | - A Denys
- INSERM, U1125, F-93017 Bobigny, France; Sorbonne Paris Cité Université Paris 13, F-93017 Bobigny, France
| | - M Petit
- INSERM, U1125, F-93017 Bobigny, France; Sorbonne Paris Cité Université Paris 13, F-93017 Bobigny, France
| | - J Biton
- INSERM, U1125, F-93017 Bobigny, France; Sorbonne Paris Cité Université Paris 13, F-93017 Bobigny, France
| | - D Lemeiter
- INSERM, U1125, F-93017 Bobigny, France; Sorbonne Paris Cité Université Paris 13, F-93017 Bobigny, France
| | - R Herve
- INSERM, U1125, F-93017 Bobigny, France; Sorbonne Paris Cité Université Paris 13, F-93017 Bobigny, France
| | - D Lutomski
- UMR 7244, Paris 13 University, Sorbonne Paris Cité, 74 rue Marcel Cachin, 93000 Bobigny, France
| | - M-C Boissier
- INSERM, U1125, F-93017 Bobigny, France; Sorbonne Paris Cité Université Paris 13, F-93017 Bobigny, France; Assistance Publique-Hôpitaux de Paris (AP-HP), Avicenne Hospital, Rheumatology Dpt, F-93009 Bobigny, France
| | - N Bessis
- INSERM, U1125, F-93017 Bobigny, France; Sorbonne Paris Cité Université Paris 13, F-93017 Bobigny, France.
| |
Collapse
|
6
|
Thiolat A, Semerano L, Pers YM, Biton J, Lemeiter D, Portales P, Quentin J, Jorgensen C, Decker P, Boissier MC, Louis-Plence P, Bessis N. Interleukin-6 receptor blockade enhances CD39+ regulatory T cell development in rheumatoid arthritis and in experimental arthritis. Arthritis Rheumatol 2014; 66:273-83. [PMID: 24504799 DOI: 10.1002/art.38246] [Citation(s) in RCA: 86] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2012] [Accepted: 09/12/2013] [Indexed: 12/16/2022]
Abstract
OBJECTIVE The rationale for blocking interleukin-6 (IL-6) in rheumatoid arthritis (RA) lies chiefly in the proinflammatory effect of this cytokine. Few studies have evaluated the consequences of anti-IL-6 receptor (IL-6R) antibody treatment on Treg cells. This study was undertaken to elucidate the mechanism of action of anti-IL-6R antibody treatment by studying the effects on Treg cells in an experimental arthritis model and in patients with RA. METHODS Mice with collagen-induced arthritis (CIA) were treated with a mouse anti-IL-6R antibody (MR16-1), and changes in Treg, Th1, and Th17 cells were assessed at key time points during the course of the disease. Peripheral blood from 15 RA patients was collected on day 0 and after 3 months of tocilizumab treatment for flow cytometry analysis of Th17 and Treg cells. RESULTS In MR16-1-treated mice, Th17 cell frequencies were unchanged, whereas Treg cell frequencies were increased. The Treg cell phenotype showed marked changes, with an increase in the frequency of CD39+ Treg cells in the lymph nodes and spleen. Interestingly, similar CD39+ Treg cell expansion was observed in RA patients who were tocilizumab responders at 3 months, with no change in Th17 cell frequency. Moreover, fluorescence-activated cell-sorted CD39+ Treg cells from responder RA patients were functionally able to suppress the proliferation of conventional T cells. CONCLUSION In both CIA and RA, the frequency of functionally suppressive CD39+ Treg cells is increased as a result of anti-IL-6R treatment, whereas Th17 cells are unaffected. The modification of Treg cell frequency and phenotype may be one of the mechanisms involved in the therapeutic effect of IL-6 blockade in RA.
Collapse
Affiliation(s)
- A Thiolat
- INSERM U1125 and Sorbonne Paris Cité Université Paris 13, Bobigny, France
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Thiolat A, Biton J, Semerano L, Lemeiter D, Boissier MC, Bessis N. SAT0042 Treatment by anti-IL-6 receptor acts on CD4+ FOXP3+ regulatory t cells in a model of rheumatoid arthritis. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.2990] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
8
|
Semerano L, Biton J, Delavallee L, Duvallet E, Assier E, Bessis N, Bernier E, Dhellin O, Grouard-Vogel G, Boissier MC. AB0172 Protection from articular damage by passive or active anti-TNF alpha immunotherapy in human-TNF alpha transgenic mice depends on anti-TNF alpha antibody levels. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
9
|
Semerano L, Biton J, Delavallée L, Duvallet E, Assier E, Bessis N, Bernier E, Dhellin O, Grouard-Vogel G, Boissier MC. Protection from articular damage by passive or active anti-tumour necrosis factor (TNF)-α immunotherapy in human TNF-α transgenic mice depends on anti-TNF-α antibody levels. Clin Exp Immunol 2013; 172:54-62. [PMID: 23480185 DOI: 10.1111/cei.12040] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/14/2012] [Indexed: 12/12/2022] Open
Abstract
Active anti-tumour necrosis factor (TNF)-α immunization with the kinoid of TNF-α (TNF-K) induces polyclonal anti-TNF-α antibodies and ameliorates arthritis in human TNF-α (hTNF-α) transgenic mice (TTg). We compared the efficacy of TNF-K to that of infliximab (IFX) and of TNF-K and IFX co-administration, and evaluated whether the titres of anti-hTNF-α antibodies induced by immunization were a determinant of TNF-K efficacy. Forty-eight TTg mice received one of the following treatments: TNF-K immunization (TNF-K group); weekly IFX throughout the study duration (IFXw0-15); TNF-K plus weekly IFX for 4 weeks (TNF-K + IFX); and weekly IFX for 4 weeks (IFXw0-4); PBS. Animals were killed at week 16. Anti-hTNF-α antibody titres and clinical and histological scores were compared. All TNF-K immunized mice (TNF-K and TNF-K + IFX) produced anti-hTNF-α antibodies. Titres were higher in TNF-K versus TNF-K + IFX (P < 0·001) and correlated inversely with histological inflammation (R = -0·78; P = 0·0001) and destruction (R = -0·67; P = 0·001). TNF-K + IFX had higher histological inflammation and destruction versus TNF-K (P < 0·05). A receiver operating characteristic (ROC) analysis of anti-hTNF-α antibody titres identified the criterion cut-off value to discriminate most effectively between the TNF-K and TNF-K + IFX groups. Mice with high versus low titres had less histological inflammation and destruction (P < 0·05). In a model of TNF-α-dependent arthritis, protection from articular damage by TNF-K correlates with the titres of induced anti-hTNF-α antibodies. The co-administration of TNF-K and a short course of infliximab does not result in less articular damage versus solely TNF-K, due probably to lower anti-hTNF-α antibody production. These results are relevant for future development of active anti-TNF-α immunization in human disease.
Collapse
Affiliation(s)
- L Semerano
- Université Paris-13 Sorbonne Paris Cité, EA4222, Paris, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Thiolat A, Biton J, Semerano L, Lemeiter D, Boissier MC, Bessis N. Anti-IL6R treatment acts on CD4+ FoxP3+ regulatory T cells in a model of rheumatoid arthritis. Ann Rheum Dis 2012. [DOI: 10.1136/annrheumdis-2011-201230.14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
11
|
Veenbergen S, Bennink MB, Affandi AJ, Bessis N, Biton J, Arntz OJ, van den Berg WB, van de Loo FAJ. A pivotal role for antigen-presenting cells overexpressing SOCS3 in controlling invariant NKT cell responses during collagen-induced arthritis. Ann Rheum Dis 2011; 70:2167-75. [DOI: 10.1136/ard.2011.154815] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
12
|
Semerano L, Biton J, Delavallee L, Duvallet E, Bernier E, Grouard-Vogel G, Boissier MC. Combination of active and passive anti-TNF treatments in human-TNF transgenic mice. Ann Rheum Dis 2011. [DOI: 10.1136/ard.2010.149013.6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
13
|
Biton J, Semerano L, Delavallee L, Lemeiter D, Laborie M, Grouard-Vogel G, Boissier MC, Bessis N. Differentiation and activation of regulatory T lymphocytes in a TNF transgenic model of arthritis, and the impact of passive or active anti-TNF therapies. Ann Rheum Dis 2011. [DOI: 10.1136/ard.2010.148981.2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
14
|
Lacroix I, Biton J, Azerad R. Microbial models of drug metabolism: microbial transformations of Trimegestone (RU27987), a 3-keto-delta(4,9(10))-19-norsteroid drug. Bioorg Med Chem 1999; 7:2329-41. [PMID: 10632043 DOI: 10.1016/s0968-0896(99)00179-0] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Screening microorganisms for the biotransformation of the 3-keto-delta(4,9(10))-19-norsteroid RU27987 (Trimegestone) resulted in the isolation of nine identified metabolites, some of them being selectively produced by different strains. Eight metabolites were found to be hydroxylated on various positions of the rings, and one was additionally epoxidized. These microbial metabolites could be used as chromatographic standards and two of them were found identical to the unknown major human metabolites. Moreover, most microbial metabolites were produced in sufficient amounts to be tested for their biological activities. All these features demonstrate the usefulness and versatility of microbial biotransformation systems as a tool for early identification and convenient production of potentially active mammalian and non-mammalian metabolites.
Collapse
Affiliation(s)
- I Lacroix
- Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, UMR 8601, Université René Descartes-Paris V, France
| | | | | |
Collapse
|
15
|
Abstract
The microbial biotransformation of HR325 [2-cyano-3-cyclopropyl-3-hydroxy-N-(4'-trifluoromethyl-3'-methylphenyl)- propenamide], a synthetic immunomodulating agent, has been investigated in order to be compared with animal metabolism and to prepare some metabolites which are difficult to obtain by chemical methods. Several fungal strains are able to completely metabolize this drug. Mortierella isabellina NRRL 1757 only achieves a benzylic hydroxylation on the aromatic methyl group, affording in high yield the corresponding hydroxymethyl derivative. In addition, other strains, such as Cunninghamella elegans ATCC 26269 or Beauveria bassiana ATCC 7159 can cleave both cyclopropyl and cyano groups in a new unknown oxidative biochemical reaction, which can be mimicked by m-chloroperbenzoate oxidation. The resulting cyanohydrin is hydrolyzed and reduced to a primary alcohol. In B. bassiana, the final incubation product is a beta-4-O-methylglucoside derivative of this alcohol, and has been fully characterized by independent synthesis. The different metabolic patterns of HR325 in the three fungal strains are discussed, and a mechanistic hypothesis about the oxidative cleavage of the right part of the molecule is proposed. The production of microbial metabolites is compared to animal metabolism in terms of structure and efficiency.
Collapse
Affiliation(s)
- I Lacroix
- Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, Unité associée au CNRS No. 400, Université René Descartes-Paris V, France
| | | | | |
Collapse
|
16
|
Biton J, Michel JM, Le Beller D, Pelenc V, Paul F, Monsan PF, Gellf G. Enzymatic synthesis of low-calorie sugar substitutes. Cellobiofructose and gentiobiofructose. Ann N Y Acad Sci 1995; 750:321-4. [PMID: 7785859 DOI: 10.1111/j.1749-6632.1995.tb19973.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Affiliation(s)
- J Biton
- Biotechnology Department, Roussel-Uclaf, Compiègne, France
| | | | | | | | | | | | | |
Collapse
|
17
|
López-Munguía A, Pelenc V, Remaud M, Biton J, Michel J, Lang C, Paul F, Monsan P. Production and purification of alternansucrase, a glucosyltransferase from Leuconostoc mesenteroides NRRL B-1355, for the synthesis of oligoalternans. Enzyme Microb Technol 1993. [DOI: 10.1016/0141-0229(93)90120-q] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|